Tenaya Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Tenaya Therapeutics, Inc. (TNYA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.20% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-08-05
- Tenaya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-06-30 was 4.20%.
- Tenaya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-03-31 was 4.50%, a 4.65% increase year-over-year.
- Tenaya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2024-03-31 was 4.30%, a 7.50% increase year-over-year.
- Tenaya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2023-09-30 was 4.40%, a 22.22% increase year-over-year.
- Tenaya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.50%, a 0.00% change from fiscal 2024.
- Tenaya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.50%, a 0.00% change from fiscal 2023.
- Tenaya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.50%, a 7.14% increase from fiscal 2022.
- Tenaya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 4.20%, a 200.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.20% 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | 4.50% 10-K · filed 2026-03-11 | |||
| 2025-09-30 | 4.50% 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | 4.20% 10-Q · filed 2026-08-05 | 4.50% 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | 4.50% 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | 4.50% 10-K · filed 2026-03-11 | |||
| 2024-09-30 | 4.50% 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | 4.50% 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | 4.30% 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | 4.50% 10-K · filed 2025-03-10 | |||
| 2023-09-30 | 4.40% 10-Q · filed 2024-11-06 | 4.40% 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | 3.90% 10-Q · filed 2024-08-08 | 4.00% 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | 4.00% 10-Q · filed 2024-05-14 | |||
| 2022-12-31 | 4.20% 10-K · filed 2024-03-18 | |||
| 2022-09-30 | 3.60% 10-Q · filed 2023-11-08 | 3.60% 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | 3.40% 10-Q · filed 2023-08-09 | 3.40% 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | 2.10% 10-Q · filed 2023-05-10 | |||
| 2021-12-31 | 1.40% 10-K · filed 2023-03-08 | |||
| 2021-09-30 | 1.20% 10-Q · filed 2022-11-10 | 1.20% 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | 1.00% 10-Q · filed 2022-08-10 | 1.00% 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | 1.00% 10-Q · filed 2022-05-11 | |||
| 2020-12-31 | 1.50% 10-K · filed 2022-03-23 | |||
| 2020-09-30 | 1.50% 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | 0.50% 10-Q · filed 2021-09-08 | 1.50% 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |